{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:00:20Z","timestamp":1794808820900,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016338","name":"Imperial Experimental Cancer Medicine Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR M4C2I1.3"],"award-info":[{"award-number":["PNRR M4C2I1.3"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUPB73C22001250006"],"award-info":[{"award-number":["CUPB73C22001250006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023178","name":"Cancer Treatment and Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jhep.2025.07.020","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:40:35Z","timestamp":1754415635000},"page":"1443-1451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-3859","authenticated-orcid":false,"given":"Giuseppe","family":"Cabibbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Celsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bhoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David James","family":"Pinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"Camm\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.07.020_bib1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jhep.2021.01.046","article-title":"Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)","volume":"74","author":"Reig","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","article-title":"Immunotherapy vs best supportive care for patients with hepatocellular cancer with child-pugh B dysfunction","volume":"10","author":"Fulgenzi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.07.020_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","article-title":"The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma","volume":"66","author":"Pinato","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","article-title":"Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death","volume":"31","author":"Cabibbo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2025.07.020_bib6","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.07.020_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2025.07.020_bib8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2025.07.020_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"10492","key":"10.1016\/j.jhep.2025.07.020_bib10","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): a randomised, open-label, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.07.020_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2025.07.020_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000529173","article-title":"Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review","volume":"12","author":"Vogel","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.07.020_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000529996","article-title":"Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: a post hoc analysis of the phase III IMbrave150 study","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2025.07.020_bib14","doi-asserted-by":"crossref","first-page":"S1451","DOI":"10.1016\/j.annonc.2024.10.151","article-title":"127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)","volume":"35","author":"Kudo","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2025.07.020_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2012.06.022","article-title":"A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI)","volume":"57","author":"Pinato","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/bjc.2012.92","article-title":"A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)","volume":"106","author":"Pinato","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2025.07.020_bib18","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2025.07.020_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.07.020_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101110","article-title":"Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC","volume":"28","author":"Pinero","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib21","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.dld.2024.02.018","article-title":"Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab","volume":"56","author":"Sultanik","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.07.020_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000562","article-title":"Atezolizumab\/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort","volume":"8","author":"de Castro","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2025.07.020_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.12.028","article-title":"Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study","author":"Stella","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib24","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"Reiberger","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.07.020_bib25","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.07.020_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"Villanueva","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2025.07.020_bib28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.07.020_bib29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","article-title":"Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease","volume":"66","author":"Lackner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib31","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1053\/j.gastro.2018.01.028","article-title":"Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis","volume":"154","author":"Simon-Talero","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2025.07.020_bib32","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/00365521.2020.1762919","article-title":"Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients","volume":"55","author":"Udumyan","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.07.020_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The Baveno VII concept of cirrhosis recompensation","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2025.07.020_bib35","article-title":"Mechanisms and implications of recompensation in cirrhosis","volume":"6","author":"Piano","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.07.020_bib36","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.07.020_bib37","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/liv.15676","article-title":"Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis","volume":"43","author":"Hofer","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2025.07.020_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.07.020_bib39","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/ueg2.12626","article-title":"Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma","volume":"12","author":"Pomej","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2025.07.020_bib40","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/HEP.0000000000000205","article-title":"Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon","volume":"77","author":"Cabibbo","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.07.020_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2022.01.122","article-title":"Italian Association for the Study of the L. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function","volume":"54","author":"Cabibbo","year":"2022","journal-title":"Dig Liver Dis"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825023864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825023864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:02:40Z","timestamp":1773457360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825023864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0168827825023864"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.07.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}